Gilead Sciences, Inc. (NASDAQ:GILD) released its first-quarter results after Thursday's closing bell. Here's a look at the details from the report. 

The Details: Gilead Sciences reported quarterly earnings of $1.81 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue came in at $6.67 billion, which missed the analyst consensus estimate of $6.77 billion and is a decrease from revenue of $6.69 billion year-over-year.

Read Next: Apple And Meta Fined Nearly $800 Million For Violating European Union’s Digital Markets Act 

For the first quarter, the company reported:

• HIV product sales increased 6% to $4.6 billion in the first quarter of 2025 compared to the same period in 2024, primarily driven by higher average realized price and demand.
• Liver Disease portfolio sales increased 3% to $758 million in the first quarter of 2025 compared to the same period in 2024. This was primarily driven by increased demand in products for primary biliary cholangitis, chronic hepatitis B virus and chronic hepatitis delta virus, partially offset by lower average realized price for chronic hepatitis C virus products.
• Veklury sales decreased 45% to $302 million in the first quarter of 2025 compared to the same period in 2024, primarily driven by lower rates of COVID-19-related hospitalizations across regions.
• Cell Therapy product sales decreased 3% to $464 million in the first quarter 2025 compared to the same period in 2024.

“Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O’Day, Gilead’s CEO.

“Our base business grew 4% year-over-year, primarily led by Biktarvy’s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer,” O’Day added.

Outlook: Gilead Sciences lowered its fiscal 2025 earnings guidance from a range of $5.95 to $6.35 per share to a range of $5.65 to $6.05 per share, versus the $6.21 estimate.

GILD Price Action: According to data from Benzinga Pro, Gilead Sciences stock was down 3.34% after hours at $102.70 on Thursday.  

Read Next: 

• Amazon Price Target Slashed Again On ‘Wild Card’ Tariff Concerns 

Photo: Shutterstock